Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
Imaging technologies for retinal biomarkers in Alzheimer’s disease
Andrew Kadis from Cambridge Vision Technology guides us through imaging technologies for retinal biomarkers in Alzheimer’s disease.
Maximising economic and societal benefits of early detection of dementia
Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers. They emphasise the importance of early detection of dementia to improve clinical outcomes for disease therapies and to maximise the economic and societal impact of this innovative new technology.
Cambridge Vision Technology – early detection of dementia
Cambridge Vision Technology (CVT) is dedicated to revolutionizing the early detection of dementia, including Alzheimer’s disease, through scientifically validated diagnostic tests based on established biomarkers.
